Dark

CVM
Cel-Sci Corporation
stock NYSEAMERICAN

At Close

May 9, 2025 3:59:30 PM EDT

0.2462USD-3.375%(-0.0086)795,933

0.2500Bid 13.00Ask 12.7500Spread

Pre-market

May 9, 2025 9:28:30 AM EDT

0.2540USD-0.314%(-0.0008)11,190

After-hours

May 9, 2025 4:09:30 PM EDT

0.2464USD+0.081%(+0.0002)504

OverviewOptionsHistoricalExchangesShortsNews

Jan 16, 2022

04:02AM EST CVM: FY21 Results; IO Revenues Analysis Benzinga

Jan 4, 2022

02:04PM EST Here's How Much $100 Invested In CEL-SCI 5 Years Ago Would Be Worth Today Benzinga

Dec 22, 2021

09:03AM EST CEL-SCI Q4 EPS $(0.19) Down From $(0.14) YoY Benzinga

Oct 22, 2021

08:11AM EDT CEL-SCI Corporation Completes Commercial-Scale Buildout Of Multikine Manufacturing Facility Benzinga

Oct 5, 2021

02:08PM EDT 2-23-10 Small Cap Market News and Stock Highlights from SmallCapVoice.com Benzinga

Sep 2, 2021

09:58AM EDT Cel-Sci Corporation Files For U.S. Patent Titled 'NOVEL PEPTIDES FOR VACCINATION AND TREATMENT OF 2019-nCoV INFECTIONS' Benzinga

Aug 29, 2021

05:21AM EDT CVM: Primum Non Nocere Benzinga

Aug 17, 2021

01:47PM EDT Mid-Day Market Update: monday.com Jumps Following Strong Q2 Results; Kubient Shares Plunge Benzinga

Aug 16, 2021

09:07AM EDT CEL-SCI Q3 EPS $(0.25) Up From $(0.27) YoY Benzinga

Jul 8, 2021

04:32PM EDT CVM: Data Has Been Released Benzinga

Jul 7, 2021

10:47AM EDT CEL SCI Form 4 Shows Purchase Of 25K Shares By CEO Geert Kersten At Average Price Of $8/Share Benzinga

Jul 6, 2021

12:15PM EDT 'The failure of a cancer drug study leaves Cel-Sci on the brink of collapse' -STAT News Report Benzinga

Jul 2, 2021

11:21AM EDT CEL-SCI Says Results Of Co's Phase 3 Trial Now Available Benzinga

Jun 28, 2021

02:40PM EDT Mid-Afternoon Market Update: Nasdaq Gains 100 Points; New Senior Investment Shares Spike Higher Benzinga

12:22PM EDT Mid-Day Market Update: Crude Oil Down Over 1%; Intellia Therapeutics Shares Jump Benzinga

11:09AM EDT UPDATE: CEL-SCI Earlier Release Showed Co. When Its Multikine Treatment Was Administered And Higher Risk Was Compared To Control, Study Did Not Achieve Its Primary Endpoint Benzinga

10:08AM EDT Mid-Morning Market Update: Markets Mixed; Perion Network Boosts FY21 Outlook Benzinga

09:46AM EDT CEL-SCI's Immunotherapy Achieves Survival Benefit Of 14% Exceeding Pre-Defined 10% In Head & Cancer Patients Benzinga

09:21AM EDT CEL-SCI Says Co's Multikine Immunotherapy Produces 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) In The Group Receiving Surgery Plus Radiotherapy In Head And Neck Cancer Phase 3 Study Benzinga

Jun 9, 2021

07:56AM EDT CEL-SCI Stock Drops After Raising $31.7M Via Secondary Equity Offering Benzinga

Jun 8, 2021

04:38PM EDT CEL-SCI Announces Bought Deal Offering For 1M Shares At $22.62/Share Benzinga

May 18, 2021

09:09AM EDT CEL-SCI Q2 EPS $(0.28) Down From $(0.25) YoY Benzinga

Mar 5, 2021

07:53AM EST Cramer Gives His Opinion On Equinix, Walgreens Boots Alliance And CEL-SCI Benzinga

Feb 16, 2021

09:05AM EST CEL-SCI Q1 EPS $(0.21) Down From $(0.16) YoY Benzinga

09:00AM EST CEL-SCI Corporation Reports First Quarter Fiscal 2021 Financial Results Business Wire

Jan 28, 2021

06:43AM EST CEL-SCI Corporation Tweeted: We want to thank those of you who have been with us for years. We almost got wiped out by the battles with short sellers and Inventiv, yet we always won. Now we are strong again and can hopefully prove that we have created a new way of treating cancer. We endured with your help! Benzinga

Jan 27, 2021

07:59PM EST Momentum/High Short Interest Stocks Rebounding From After-Hours Lows Benzinga

Jan 8, 2021

08:30AM EST CEL-SCI Corporation to Present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference Business Wire

Jan 4, 2021

09:24AM EST CEL-SCI Says Focusing On First, Advanced Primary Head And Neck Cancer; Awaiting Final Results Of Phase 3 Study RTTNews

09:18AM EST CEL-SCI Corporation Issues Letter To Shareholders (Full Statement) Benzinga

09:15AM EST CEL-SCI Corporation Issues Letter to Shareholders Business Wire

Dec 30, 2020

08:15AM EST CEL-SCI Corp. Posts Wider Loss In FY20 - Quick Facts RTTNews

08:06AM EST CEL-SCI FY Net Loss $30.3 Mln Vs Net Loss $22.1 Mln Last Year RTTNews

08:00AM EST CEL-SCI Reports Fiscal 2020 Financial Results and Clinical & Corporate Developments Business Wire

Dec 29, 2020

05:08PM EST Cel-Sci Announces Financial Statements Within Quarterly Reports For Qtr Ended Dec 31, 2019, March 31, 2020, & June 30, 2020 Should Not Be Relied Upon Benzinga

Dec 14, 2020

08:30AM EST CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference Business Wire

Dec 11, 2020

11:29AM EST CEL-SCI Announces the Closing of Its $14.65 Million Bought Deal Business Wire

Dec 8, 2020

07:40PM EST CEL-SCI Says Underwriters Agrees To Purchase On Firm Commitment Basis Minimum Of 1 Mln Shares At Price Of $14.65/shr RTTNews

06:44PM EST CEL-SCI Announces Bought Deal Offering Business Wire

Dec 7, 2020

09:37AM EST CEL-SCI: Phase 3 Study Is In Final Stage Of Review Which Involves Statistical Analysis Of All Study Data RTTNews

09:15AM EST CEL-SCI Announces Update on Phase 3 Cancer Trial Results Business Wire

Dec 1, 2020

09:12AM EST CEL-SCI Corporation Highlights Study Showing Its LEAPS COV-19 Peptides Achieved A 40% Survival Rate In Transgenic Mouse Models Benzinga

09:00AM EST CEL-SCI's LEAPS Peptides Demonstrate Clear Survival Benefit as a Treatment for COVID-19 in Preclinical Studies Business Wire

Nov 6, 2020

05:04PM EST IIROC Trading Resumption - CVM PR Newswire

Oct 29, 2020

01:26PM EDT IIROC Trading Halt - CVM PR Newswire

Oct 7, 2020

08:55AM EDT 'More evidence today pointing to buried failure of $CVM Multikine ph3. It comes from Bristol, which reports positive outcome of Opdivo+chemo in neoadjuvant tx of resectable NSCLC. The primary endpoint was pathologic complete response' -Tweet Benzinga

Sep 18, 2020

09:11AM EDT CEL-SCI Secures European Patent For LEAPS Vaccine In Treatment Of Rheumatoid RTTNews

09:00AM EDT CEL-SCI Wins European Patent For LEAPS Vaccine In Treatment Of Rheumatoid Arthritis Benzinga

09:00AM EDT CEL-SCI Awarded European Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis Business Wire

Sep 15, 2020

09:31AM EDT '$CVM delays indefinitely the readout from its Multikine phase 3 study, blaming Covid-19...' -Tweet From STAT News' Adam Feuerstein Benzinga

09:16AM EDT CEL-SCI Corporation Issues Letter To Shareholder Benzinga

Sep 11, 2020

09:00AM EDT CEL-SCI Corporation to Present at H.C. Wainwright 22nd Annual Global Investment Conference Business Wire

Aug 31, 2020

04:16PM EDT IIROC Trading Resumption - CVM PR Newswire

Aug 11, 2020

08:43AM EDT CEL-SCI Q3 Net Loss Narrows To $10.2 Mln From $12.1 Mln Prior Year RTTNews

08:34AM EDT CEL-SCI Q3 EPS $(0.27) Up From $(0.37) YoY Benzinga

08:30AM EDT CEL-SCI Corporation Reports Third Quarter Fiscal 2020 Financial Results Business Wire

Jul 24, 2020

10:00AM EDT CEL-SCI shares are trading higher after the company announced it completed animal experiments with LEAPS coronavirus conjugate, which provides the basis for moving forward into animal challenge studies with live virus SARS-CoV-2. Benzinga

09:46AM EDT CEL-SCI Corp. (CVM) said that it has concluded animal experiments using its LEAPS COVID 19 conjugate that provide the basis for moving forward into animal challenge studies with live virus SARS-CoV-2, the causative agent of COVID 19, at the University of Georgia Vaccine Center. RTTNews

08:33AM EDT CEL-SCI Reports Early Results With COVID 19 LEAPS Vaccine/Treatment RTTNews

08:31AM EDT CEL-SCI Reports Completed Animal Experiments With LEAPS Coronavirus Conjugate That Provided Basis for Moving Forward Into Animal Challenge Studies With Live Coroanvirus Benzinga

08:30AM EDT CEL-SCI Announces Early Results with COVID 19 LEAPS Vaccine/Treatment Business Wire